Q3FY2026 revenue grew 12% YoY to ₹2,692 crores with improved margins; three Custom Synthesis facilities expected to commercialize in Q4 FY'27.
🔄 What Changed
Gross margin expanded via Custom Synthesis mix shift (57% of product mix vs prior year), capacity utilization 70-85%, GLP-1 pilot plant completed, gross asset turnover target 1.5-1.8x (vs current 1.19x within 4-5 years)
🔮 What's Next
Three dedicated Custom Synthesis facilities to commercialize Q4 FY'27 onwards; Phase 2 Kakinada expansion (4 production blocks) under evaluation; protected amino acids and peptide fragments in validation with revenue ramp-up pending regulatory approval
💡 Investor Takeaway
Strong margin improvement and Custom Synthesis growth momentum position Divi's for double-digit expansion, but near-term earnings growth may face headwinds from generic pricing pressure and validation timelines for new peptide/GLP-1 products.
⚠️ Risks
Generic API pricing pressures persist despite volume growth; forex exposure not hedged; customer contracts subject to confidentiality limiting disclosure; regulatory approvals required for customer commercialization
Divi's Laboratories reported Q3FY2026 consolidated revenue of **₹2,692 crores** (up **12%** YoY) with PBT before exceptional items at **₹854 crores** versus **₹726 crores** prior year. Material consumption improved to **36.3%** from **39.8%**, driven by strong Custom Synthesis growth (**57%** of product mix). The company achieved **89%** export intensity with **73%** from Europe/US. Management expects three dedicated Custom Synthesis facilities to commercialize in Q4 FY'27, with capacity utilization at **70-85%** and FY'26 capex guidance revised to **₹1,900 crores**. FDA CGMP inspection passed; Unit 3 backward integration progresses. Double-digit growth is targeted despite generic pricing pressures.
Recent Announcements from Divi's Laboratories Limited
🟡 Board Meeting — 11 June 2026
Divi's Laboratories announced a ₹30 per share dividend for FY2025-26, payable after August 14, 2026, to shareholders on record as of July 24, 2026, su...
🔴 Financial Results — 23 May 2026
Divi's Laboratories announced that the audio recording of its Q4 FY26 earnings conference call held on May 23, 2026, is now available on its website u...
🔴 Financial Results — 31 March 2026
Divi's Laboratories announced closure of its trading window effective April 1, 2026, ahead of audited financial results for the quarter and year ended...
🔴 Announcement — 21 March 2026
Divi's Laboratories received a Draft Assessment Order from the Income Tax Authority for FY2022-23 proposing **₹570.51 crores** in additions/disallowan...
Announcement — 14 March 2026
Divi's Laboratories Limited published newspaper advertisements on March 14, 2026, announcing the opening of a special window for transfer and demateri...
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.